VIDEO: Real-world studies show benefits of faricimab in neovascular AMD
Click Here to Manage Email Alerts
In this Healio Video Perspective, Theodore Leng, MD, FACS, discusses the real-world use of faricimab for neovascular age-related macular degeneration.
The data, presented at the Retina Society meeting, are from the FARETINA and FARWIDE studies, which took place in the United States and the United Kingdom, respectively.
“The FARETINA and the FARWIDE real-world studies are the largest ongoing registry studies of faricimab, and additional analyses are planned as the data continues to grow and mature,” Leng said.
Collapse
Leng T. Early treatment patterns and outcomes in neovascular age-related macular degeneration
(nAMD) patients initiating faricimab in the US and UK. Presented at: Retina Society meeting; Oct. 11-14, 2023; New York.
Read more about
Click Here to Manage Email Alerts